Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Lorlatinib

329c5865-4954-51b6-9da4-eb7358603488 · FDA Approved · targets ALK

Lorlatinib

MeasuredReference

Lorlatinib targets ROS_ROS1, TNK2, FER. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

ROS_ROS1TNK2FERFAK_PTK2PTK2B

Top hallmarks

  • tumor promoting inflammation2.1k
  • proliferation1.6k
  • evading apoptosis1.5k

Top pathways disrupted

  • allograft rejection3.8k
  • apical junction3.7k
  • pi3k akt mtor signaling3.6k

Resistance landscape — Lorlatinib

MeasuredReference

No variant annotations found on Lorlatinib's top targets.

No variant annotations on Lorlatinib's top targets.
Open in new tab